Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Donna Zarycranski"'
Autor:
Gerard J. Meskill, Craig W. Davis, Donna Zarycranski, Markiyan Doliba, Jean-Charles Schwartz, Jeffrey M. Dayno
Publikováno v:
CNS Drugs
Background Pitolisant, a selective histamine 3 receptor antagonist/inverse agonist, is indicated for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The efficacy and safety of pitolisant have been demonstrated in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af53da85d1b0a62b8568257f9be471ee
https://doi.org/10.1007/s40263-021-00886-x
https://doi.org/10.1007/s40263-021-00886-x
Autor:
Audrey Wells, David Albers, Markiyan Doliba, Donna Zarycranski, Jean-Charles Schwartz, Jeffrey Dayno
Publikováno v:
SLEEP. 46:A253-A254
Introduction Narcolepsy is characterized by symptoms indicative of sleep–wake dysregulation, notably excessive daytime sleepiness (EDS) and cataplexy. In 2021, the American Academy of Sleep Medicine (AASM) updated its clinical practice guidelines o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6cefbb63abae03dbc963743d283b96f6
https://doi.org/10.1093/sleep/zsad077.0577
https://doi.org/10.1093/sleep/zsad077.0577
Autor:
Nathaniel F. Watson, Jeffrey M Dayno, Ben Vaughn, Donna Zarycranski, Craig W. Davis, Yves Dauvilliers, Jean-Charles Schwartz
Publikováno v:
CNS Drugs
Background Pitolisant is approved in the USA and Europe for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. Objective Analyses evaluated the time to onset of clinical response during treatment with pitolisant. Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbe886b2ef564a766764b0b35d1d14ca
http://europepmc.org/articles/PMC8642365
http://europepmc.org/articles/PMC8642365
Autor:
Gerard Meskill, Craig Davis, Donna Zarycranski, Markiyan Doliba, Jean-Charles Schwartz, Jeffrey Dayno
Publikováno v:
Sleep. 45:A172-A172
Introduction This post hoc analysis evaluated the clinical impact of pitolisant for the reduction of excessive daytime sleepiness (EDS) and cataplexy in adults with a high burden of narcolepsy symptoms. When evaluating results of randomized, placebo-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f142001e17a69fa1ecb94106e352c478
https://doi.org/10.1093/sleep/zsac079.380
https://doi.org/10.1093/sleep/zsac079.380
Autor:
BA Kelly A. Manser, DO Gwendolyn Niebler, Donna Zarycranski, Colville Brown, Simon H. Budman, Stacey McCaffrey, Kimberlee J. Trudeau
Publikováno v:
Journal of Opioid Management. 14:397-405
Objective: The purpose of this retrospective, observational pilot study was to explore change in route of administration (RoA) and motivation for changing RoA during the course of opioid abuse. Design: This retrospective pilot study involved collecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::093130cb47ece22ce4050b0309517c02
https://doi.org/10.5055/jom.2018.0472
https://doi.org/10.5055/jom.2018.0472
Autor:
Markiyan Doliba, Donna Zarycranski, Jean-Charles Schwartz, Jeffrey M Dayno, Gerard J Meskill, Craig W. Davis
Publikováno v:
Sleep. 44:A198-A199
Introduction When evaluating results of randomized, placebo-controlled trials, the clinical impact of a treatment can be assessed using number needed to treat (NNT; number of patients that need to be treated to achieve a specific outcome for one pers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::28147c38a01925610efb3c28b0df9f54
https://doi.org/10.1093/sleep/zsab072.503
https://doi.org/10.1093/sleep/zsab072.503